Newfeed

SAN DIEGO, April 8, 2024 /PRNewswire/ — Akeso, Inc. (9926.HK) today announced that the positive interim analysis results from Phase III clinical study of Cadonilimab (PD-1/CTLA-4 BsAb) combined with XELOX (capecitabine plus oxaliplatin) as first-line treatment for unresectable locally advanced

REHOVOT, Israel, April 8, 2024 /PRNewswire/ — Nova (Nasdaq: NVMI), today announced the promotion of Mr. Guy Kizner to the position of Chief Financial Officer, effective July 1st, 2024. Joining the leadership team, Mr. Kizner will succeed Mr. Dror David, who joined Nova in 1998 and has served

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: